“…This variability is even more potentiated in cancer cells [29]. In general, GSTP1 over-expression seems to be a hallmark of proliferating cells in many solid tumors, including transitional cell carcinoma of urinary bladder [30,31], renal cell carcinoma [32,33], ovarian cancer [34,35], breast cancer [36,37] and colorectal cancer [38,39]. Regarding other GST classes, increased expression of GSTA1 is confirmed in colorectal cancer [39], GSTO1-1 is upregulated in transitional cell carcinoma [40], esophageal squamous cell carcinoma [41], pancreatic cancer [42], and breast cancer [43], while GSTM1 overexpression is observed in transitional cell carcinoma of urinary bladder [31], renal cell carcinoma [33] and breast cancer [44].…”